Basal-like and triple-negative breast cancers. Searching for positives among many negatives

Surgical Oncology Clinics of North America

Volumn 23, Issue 3, 2014, Pages 567-577

  Alluri, Prasanna ^a   Newman, Lisa A ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Basal breast cancer; Breast cancer subtypes; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADVANCED CANCER; BASAL LIKE BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; BLACK PERSON; ETHNOLOGY; FEMALE; GENETICS; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

AFRICAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; RISK FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84901586809     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2014.03.003     Document Type: Review

References (46)

1. Brenton J.D., Carey L.A., Ahmed A.A., et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. JClin Oncol 2005, 23(29):7350-7360.
2. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
3. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. NEngl J Med 2010, 363(20):1938-1948.
4. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with. Proc Natl Acad Sci USA 2001, 98(19):10869-10874.
5. Bertucci F., Finetti P., Cervera N., et al. How basal are triple-negative breast cancers?. Int J Cancer 2008, 123(1):236-240.
6. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15 Pt 1):4429-4434.
7. Ho A.Y., Gupta G., King T.A., et al. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer 2012, 118(20):4944-4952.
8. Collett K., Stefansson I.M., Eide J., et al. Abasal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1108-1112.
9. Foulkes W.D., Stefansson I.M., Chappuis P.O., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. JNatl Cancer Inst 2003, 95(19):1482-1485.
10. Hartman A.R., Kaldate R.R., Sailer L.M., et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 2012, 118(11):2787-2795.
11. Hutchinson L. Screening: BRCA testing in women younger than 50 with triple-negative breast cancer is cost effective. Nat Rev Clin Oncol 2010, 7(11):611.
12. Andres R., Pajares I., Balmana J., et al. Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). Clin Transl Oncol 2014, 16(3):280-284.
13. Rummel S., Varner E., Shriver C.D., et al. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat 2013, 137(1):119-125.
14. Millikan R.C., Newman B., Tse C.K., et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109(1):123-139.
15. Yang X.R., Sherman M.E., Rimm D.L., et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007, 16(3):439-443.
16. Phipps A.I., Chlebowski R.T., Prentice R., et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. JNatl Cancer Inst 2011, 103(6):470-477.
17. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-2502.
18. Kurian A.W., Fish K., Shema S.J., et al. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res 2010, 12(6):R99.
19. Amirikia K.C., Mills P., Bush J., et al. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 2011, 117(12):2747-2753.
20. Nelson H.D., Tyne K., Naik A., et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 151(10):727-737. W237-42.
21. Fregene A., Newman L.A. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women?. Cancer 2005, 103(8):1540-1550.
22. Stark A., Kleer C.G., Martin I., et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 2010, 116(21):4926-4932.
23. Huo D., Ikpatt F., Khramtsov A., et al. Population differences in breast cancer: survey in indigenous African women. JClin Oncol 2009, 27(27):4515-4521.
24. Burson A.M., Soliman A.S., Ngoma T.A., et al. Clinical and epidemiologic profile of breast cancer in Tanzania. Breast Dis 2010, 31(1):33-41.
25. Schwartz T., Stark A., Pang J., et al. Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women. Cancer 2013, 119(3):488-494.
26. Resetkova E., Reis-Filho J.S., Jain R.K., et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010, 123(1):97-108.
27. Fejerman L., Haiman C.A., Reich D., et al. An admixture scan in 1,484 African American women with breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18(11):3110-3117.
28. Palmer J.R., Ruiz-Narvaez E.A., Rotimi C.N., et al. Genetic susceptibility loci for subtypes of breast cancer in an African American population. Cancer Epidemiol Biomarkers Prev 2013, 22(1):127-134.
29. Turner N.C., Reis-Filho J.S., Russell A.M., et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007, 26(14):2126-2132.
30. Tutt A., Robson M., Garber J.E., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376(9737):235-244.
31. Hiller D.J., Chu Q.D. Current Status of Poly(ADP-ribose) polymerase inhibitors as novel therapeutic agents for triple-negative breast cancer. Int J Breast Cancer 2012, 2012:829315.
32. Dantzer F., de La Rubia G., Menissier-De Murcia J., et al. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose). Biochemistry 2000, 39(25):7559-7569.
33. Hastak K., Alli E., Ford J.M. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010, 70(20):7970-7980.
34. O'Shaughnessy J., Osborne C., Pippen J.E., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. NEngl J Med 2011, 364(3):205-214.
35. Crown J., O'Shaughnessy J., Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 2012, 23(Suppl 6):vi56-vi65.
36. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of. Clin Cancer Res 2004, 10(16):5367-5374.
37. Carey L.A., Rugo H.S., Marcom P.K., et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. JClin Oncol 2012, 30(21):2615-2623.
38. Baselga J., Gómez P., Greil R., et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. JClin Oncol 2013, 31(20):2586-2592.
39. Linderholm B.K., Hellborg H., Johansson U., et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009, 20(10):1639-1646.
40. O'Shaughnessy J., Romieu G., Diéras V., et al. Meta-analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res 2010, 70(Suppl 24). [Abstract P6-12-03].
41. Brufsky A., Valero V., Tiangco B., et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012, 133(3):1067-1075.
42. O'Toole S.A., Beith J.M., Millar E.K., et al. Therapeutic targets in triple negative breast cancer. JClin Pathol 2013, 66(6):530-542.
43. Shah S.P., Roth A., Goya R., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486(7403):395-399.
44. Lehmann B.D., Bauer J.A., Chen X., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. JClin Invest 2011, 121(7):2750-2767.
45. Speers C., Tsimelzon A., Sexton K., et al. Identification of novel kinase targets for the treatment of estrogen. Clin Cancer Res 2009, 15(20):6327-6340.
46. Kothari V., Wei I., Shankar S., et al. Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov 2013, 3(3):280-293.